Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists |
Mechanism MRGPRX2 antagonists(MAS related GPR family member X2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC22H23ClF3N5O |
InChIKeyQFTGJWCFBYRISW-UHFFFAOYSA-N |
CAS Registry3075831-93-2 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Inflammation | Preclinical | United States | 02 Jun 2025 |





